← Back

Wire · operational-macro

FDA clears phase 1/2 trial of androgen receptor antagonist in mCRPC

Published

17 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at urologytimes.com →

◆ Verified

Fusion42 · 17 November 2026 · Fusion42 review

The FDA has cleared an Investigational New Drug application for EIK1006, enabling a first-in-human phase 1/2 trial targeting metastatic androgen pathway modulation-resistant prostate cancer. EIK1006 is designed to inhibit both wild-type androgen receptors and resistant variants, with patient dosing expected to start in 2027.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a clearer regulatory path to launch new prostate cancer therapies targeting resistant androgen receptors. Prepare to accelerate patient recruitment and partnerships for your clinical studies starting next year.

◆ Coverage

1 source · 17 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-clearanceclinical-trialprostate-cancerandrogen-receptorpharma-development